Altogether, tumor-resident CD8+ TRMs act as dynamic epithelial sentinels that integrate antigenic, adhesive, and cytokine cues to maintain residency and sustain cytotoxic competence, representing a critical target for next-generation immunotherapies. This evidence concerns the gene CD8A and neoplasm.